ALternative TEnofovir Dosing in Adults With Moderate Renal Function Impairment (ALTER)
To assess the drug concentrations of tenofovir (TDF) in HIV-infected Thai adults with moderate renal function impairment when administered at the recommended dose of 300 mg every 48 hours, and at an alternative dose of 150 mg every 24 hours.
|Study Design:||Endpoint Classification: Pharmacokinetics Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
|Official Title:||Tenofovir Pharmacokinetics in HIV-infected Thai Adults With Moderate Renal Function Impairment Receiving Either Efavirenz-based or Lopinavir/Ritonavir-based Antiretroviral Therapy|
- Tenofovir plasma area-under the concentration time curve (AUC) [ Time Frame: Study Entry and Day 14 ] [ Designated as safety issue: No ]For each patient, ratios of AUC0-last of q24h versus q48h will be calculated. Geometric mean ratios (GMRs) with 90% CI will be calculated after log-transformation of within patient ratios.
|Study Start Date:||August 2012|
|Estimated Study Completion Date:||August 2013|
|Estimated Primary Completion Date:||April 2013 (Final data collection date for primary outcome measure)|
|Experimental: Tenofovir-containing HAART||
Other: Tenofovir Dose Adjustment
In subjects with a confirmed CLcr 30 to <50 mL/min, switch tenofovir 300 mg every 48 hours, to 150 mg once daily for 2 weeks.
The study is designed as a Phase I, non-randomized, open-label, pharmacokinetic study. We hypothesize that administration of tenofovir 150 mg once daily to HIV-infected Thai adults with moderate renal function impairment (CLcr between 30 to <50 mL/min) will provide comparable drug exposure to the current recommended dose of 300 mg every 48 hours.
Confirmed HIV-positive subjects receiving tenofovir (TDF) 300 mg, every 48 hours, as part of an efavirenz (EFV)-based or lopinavir/ritonavir (LPV/r)-based HAART regimen will be proposed to participate.
Subjects meeting the required criteria will be enrolled into one of 2 groups depending on their HAART regimen: .
Group 1: Subjects receiving tenofovir 300 mg, every 48 hours, in combination with lamivudine and efavirenz ,and a confirmed CLcr 30 to <50 mL/min
Group 2: Subjects receiving tenofovir 300 mg, every 48 hours, in combination with lamivudine and lopinavir/ritonavir, and a confirmed CLcr 30 to <50 mL/min
The study procedures are identical for both groups. All subjects enrolled will have two study visits. At the first visit, a 48-hour pharmacokinetic evaluation will be performed. Immediately following completion of the PK sampling, the tenofovir dose will be changed to 150 mg, once daily. Two weeks later, at the second visit, a 24-hour pharmacokinetic evaluation will be performed. Following completion of the second PK sampling the tenofovir dose will be changed back to 300 mg every 48 hours. At this time the subjects has reach the end of the study.
|Contact: Tim R Cressey, PhD||+66 53 email@example.com|
|Contact: Gonzague Jourdain, MD, PhD||+66 5381 9125||Gonzague.Jourdain@phpt.org|
|Sanpatong, Chiang Mai, Thailand, 20120|
|Contact: Virat Klinbuayaem, MD firstname.lastname@example.org|
|Principal Investigator: Virat Klinbuayaem, MD|
|HIV-NAT||Not yet recruiting|
|Bangkok, Thailand, 10330|
|Contact: Anchalee Avihingsanon, MD 02-652-3040 email@example.com|
|Principal Investigator: Anchalee Avihingsanon, MD|
|Chonburi, Thailand, 20000|
|Contact: Chureeratana Bowonwatanuwong, MD 03893 1000 firstname.lastname@example.org|
|Principal Investigator: Chureeratana Bowonwatanuwong, MD|
|Phayao, Thailand, 56000|
|Contact: Guttiga Halue, MD email@example.com|
|Principal Investigator: Guttiga Halue, MD|
|Principal Investigator:||Tim R Cressey, PhD||PHPT / Chiang Mai University / IRD|